Literature DB >> 26113424

A venous thromboembolism risk assessment model for patients with Cushing's syndrome.

Marialuisa Zilio1, Linda Mazzai2, Maria Teresa Sartori3, Mattia Barbot2, Filippo Ceccato2, Viviana Daidone3, Alessandra Casonato3, Graziella Saggiorato3, Franco Noventa4, Laura Trementino5, Paolo Prandoni3, Marco Boscaro2, Giorgio Arnaldi5, Carla Scaroni2.   

Abstract

Cushing's syndrome (CS) is associated with an incidence of venous thromboembolism (VTE) about ten times higher than in the normal population. The aim of our study was to develop a model for identifying CS patients at higher risk of VTE. We considered clinical, hormonal, and coagulation data from 176 active CS patients and used a forward stepwise logistic multivariate regression analysis to select the major independent risk factors for thrombosis. The risk of VTE was calculated as a 'CS-VTE score' from the sum of points of present risk factors. VTE developed in 20 patients (4 pulmonary embolism). The group of CS patients with VTE were older (p < 0.001) and had more cardiovascular events (p < 0.05), infections and reduced mobility (both p < 0.001), higher midnight plasma cortisol levels (p < 0.05), and shorter APTT (p < 0.01) than those without. We identified six major independent risk factors for VTE: age ≥69 years and reduced mobility were given two points each, whereas acute severe infections, previous cardiovascular events, midnight plasma cortisol level >3.15 times the normality and shortened APTT were given one point each. A CS-VTE score <2 anticipated no risk of VTE; a CS-VTE score of two mild risk (10 %); a CS-VTE score of three moderate risk (46 %); a CS-VTE score ≥4 high risk (85 %). Considering a score ≥3 as predictive of VTE, 94 % of the patients were correctly classified. A simple score helps stratify the VTE risk in CS patients and identify those who could benefit from thromboprophylaxis.

Entities:  

Keywords:  Cushing’s syndrome; Model; Risk; Score; Venous thromboembolism

Mesh:

Year:  2015        PMID: 26113424     DOI: 10.1007/s12020-015-0665-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  42 in total

Review 1.  Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors.

Authors:  B van Zaane; E Nur; A Squizzato; V E A Gerdes; H R Büller; O M Dekkers; D P M Brandjes
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

2.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score.

Authors:  S Barbar; F Noventa; V Rossetto; A Ferrari; B Brandolin; M Perlati; E De Bon; D Tormene; A Pagnan; P Prandoni
Journal:  J Thromb Haemost       Date:  2010-11       Impact factor: 5.824

3.  "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.

Authors:  P Simioni; A Scudeller; P Radossi; S Gavasso; B Girolami; D Tormene; A Girolami
Journal:  Thromb Haemost       Date:  1996-03       Impact factor: 5.249

4.  Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome.

Authors:  Marco Boscaro; Nicoletta Sonino; Alessandro Scarda; Luisa Barzon; Francesco Fallo; Maria T Sartori; Giovanni M Patrassi; Antonio Girolami
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

5.  Multisystem morbidity and mortality in Cushing's syndrome: a cohort study.

Authors:  Olaf M Dekkers; Erzsébet Horváth-Puhó; Jens Otto L Jørgensen; Suzanne C Cannegieter; Vera Ehrenstein; Jan P Vandenbroucke; Alberto M Pereira; Henrik Toft Sørensen
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

6.  Late-night salivary cortisol as a screening test for Cushing's syndrome.

Authors:  H Raff; J L Raff; J W Findling
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

7.  The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia.

Authors:  Maria Teresa Sartori; Cristina Danesin; Graziella Saggiorato; Daniela Tormene; Paolo Simioni; Luca Spiezia; Giovanni Maurizio Patrassi; Antonio Girolami
Journal:  Clin Appl Thromb Hemost       Date:  2003-10       Impact factor: 2.389

8.  Performance of salivary cortisol in the diagnosis of Cushing's syndrome, adrenal incidentaloma, and adrenal insufficiency.

Authors:  Filippo Ceccato; Mattia Barbot; Marialuisa Zilio; Sergio Ferasin; Gianluca Occhi; Andrea Daniele; Sara Mazzocut; Maurizio Iacobone; Corrado Betterle; Franco Mantero; Carla Scaroni
Journal:  Eur J Endocrinol       Date:  2013-06-01       Impact factor: 6.664

9.  Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome.

Authors:  Alessandra Casonato; Viviana Daidone; Francesca Sartorello; Nora Albiger; Chiara Romualdi; Franco Mantero; Antonio Pagnan; Carla Scaroni
Journal:  Br J Haematol       Date:  2008-01       Impact factor: 6.998

10.  Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome.

Authors:  L M Fatti; B Bottasso; C Invitti; R Coppola; F Cavagnini; P M Mannucci
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 5.467

View more
  13 in total

Review 1.  A systematic review of mobility/immobility in thromboembolism risk assessment models for hospitalized patients.

Authors:  Fan Ye; Carolyn Stalvey; Matheen A Khuddus; David E Winchester; Hale Z Toklu; Joseph J Mazza; Steven H Yale
Journal:  J Thromb Thrombolysis       Date:  2017-07       Impact factor: 2.300

2.  Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.

Authors:  Mattia Barbot; Valentina Guarnotta; Marialuisa Zilio; Filippo Ceccato; Alessandro Ciresi; Andrea Daniele; Giuseppe Pizzolanti; Elena Campello; Anna Chiara Frigo; Carla Giordano; Carla Scaroni
Journal:  Endocrine       Date:  2018-07-06       Impact factor: 3.633

3.  CUSHING'S SYNDROME, A RISK FACTOR FOR VENOUS THROMBOEMBOLISM IS A CANDIDATE FOR GUIDELINES.

Authors:  G Koraćević; M Stojanović; S Petrović; D Simić; D Sakač; M Vlajković; M Stevic; M Kocić; M Đorđević; M Koraćević
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Apr-Jun       Impact factor: 0.877

Review 4.  Consensus on diagnosis and management of Cushing's disease: a guideline update.

Authors:  Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller
Journal:  Lancet Diabetes Endocrinol       Date:  2021-10-20       Impact factor: 32.069

Review 5.  Hypercoagulability in Cushing's syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols.

Authors:  Richard A Feelders; Lynnette K Nieman
Journal:  Pituitary       Date:  2022-07-26       Impact factor: 3.599

6.  Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.

Authors:  Armando Tripodi; Concetta T Ammollo; Fabrizio Semeraro; Mario Colucci; Elena Malchiodi; Elisa Verrua; Emanuele Ferrante; Giorgio Arnaldi; Laura Trementino; Lidia Padovan; Veena Chantarangkul; Flora Peyvandi; Giovanna Mantovani
Journal:  Endocrine       Date:  2016-07-22       Impact factor: 3.633

7.  Is VTE Prophylaxis Necessary on Discharge for Patients Undergoing Adrenalectomy for Cushing Syndrome?

Authors:  Bruna Babic; Amory De Roulet; Anita Volpe; Naris Nilubol
Journal:  J Endocr Soc       Date:  2018-12-12

Review 8.  Glucocorticoid excess and COVID-19 disease.

Authors:  Valentina Guarnotta; Rosario Ferrigno; Marianna Martino; Mattia Barbot; Andrea M Isidori; Carla Scaroni; Angelo Ferrante; Giorgio Arnaldi; Rosario Pivonello; Carla Giordano
Journal:  Rev Endocr Metab Disord       Date:  2020-10-06       Impact factor: 6.514

9.  Selected Biomarkers Correlate with the Origin and Severity of Sepsis.

Authors:  Michal Holub; Olga Džupová; Michaela Růžková; Alžběta Stráníková; Eva Bartáková; Jan Máca; Jiří Beneš; Heiko Herwald; Ondřej Beran
Journal:  Mediators Inflamm       Date:  2018-03-27       Impact factor: 4.711

10.  Hypercoagulability in Cushing Syndrome, Prevalence of Thrombotic Events: A Large, Single-Center, Retrospective Study.

Authors:  Maria Gabriela Suarez; Madeleine Stack; Jose Miguel Hinojosa-Amaya; Michael D Mitchell; Elena V Varlamov; Chris G Yedinak; Justin S Cetas; Brett Sheppard; Maria Fleseriu
Journal:  J Endocr Soc       Date:  2019-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.